Cowed by a fierce and lighting-quick backlash fueled by angry Tweets and Facebook posts, The Susan G. Komen for the Cure Foundation is backpedaling, but is it too late to reverse the reputation damage?

Allergan removed records from its website that had detailed payments made to doctors from the middle of 2010 through first-half 2011.

Jobson Medical Information Holdings filed for chapter 11 bankruptcy in New York Thursday, the company said, part of an effort to amend and extend its credit and strengthen its balance sheet.

Merck said Thursday its ownership of the global marketplace for DPP-IV diabetes drugs helped it close out the quarter with $12.3 billion in sales, and $48 billion in sales for the year. The two drugs behind the boost were Januvia, which saw a 42% bump in fourth quarter sales, and Janumet, which saw sales jump 34% for the quarter.

AstraZeneca confirmed rumors of another round of deep cuts, announcing that it will eliminate 7,300 positions throughout the company.

The Healthcare Businesswomen's Association named Ernst & Young global pharma lead Carolyn Buck Luce, calling her "a dedicated leader promoting women's advancement in healthcare."

Procter & Gamble is looking to lower its promotion costs by leaning more on digital media, Chairman and CEO Bob McDonald told analysts in an earnings call.

J&J is pushing back hard against a Wall Street Journal article suggesting that a pair of retirements and a promotion are part of a corporate shakeup of its recall-plagued McNeil Consumer Healthcare division.

An online protest, which had more than 2,500 supporters as of Wednesday morning, has pulled the scientific publishing industry into a fight between the publishers and the published.

An FDA study looking at the power of background visuals to distract viewers from the often-ominous risk info read in the "major statement" section of TV drug ads found no evidence that consumer understanding of risk info is affected by the "emotional (affective) tone of images.

FDA's first draft guidance to come out of its 2009 online communication hearing offers sound counsel but not much in the way of specifics, writes Peter Pitts. The takeaway: where the letter of the law is hazy, exercise your judgement and follow, as best you can, the spirit of the law.

FDA's recent draft guidance on off-label communication is, despite its shortcomings, a step forward, writes John Kamp, arguing that pharmas should take this welcome bit of clarity and act boldly on it